Progress in understanding Friedreich’s ataxia using human induced pluripotent stem cells

References

• Koeppen AH. Friedreich’s ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011;303(1–2):1–12.
   PubMed Web of Science ®Google Scholar
• Delatycki MB, Corben LA. Clinical features of Friedreich ataxia. J Child Neurol. 2012;27(9):1133–1137.
   PubMed Web of Science ®Google Scholar
• Campuzano V, Montermini L, Molto MD, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423–1427.
   PubMed Web of Science ®Google Scholar
• Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med. 1996;335(16):1169–1175.
   PubMed Web of Science ®Google Scholar
• Clark E, Butler JS, Isaacs CJ, et al. Selected missense mutations impair frataxin processing in Friedreich ataxia. Ann Clin Transl Neurol. 2017;4(8):575–584.
   PubMed Web of Science ®Google Scholar
• Long A, Napierala JS, Polak U, et al. Somatic instability of the expanded GAA repeats in Friedreich’s ataxia. PLoS One. 2017;12(12):e0189990.
   PubMed Web of Science ®Google Scholar
• De Biase I, Rasmussen A, Monticelli A, et al. Somatic instability of the expanded GAA triplet-repeat sequence in Friedreich ataxia progresses throughout life. Genomics. 2007;90(1):1–5.
   PubMed Web of Science ®Google Scholar
• Pandolfo M, Pastore A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol. 2009;256(Suppl 1):9–17.
   PubMedGoogle Scholar
• Colin F, Martelli A, Clemancey M, et al. Mammalian frataxin controls sulfur production and iron entry during de novo Fe4S4 cluster assembly. J Am Chem Soc. 2013;135(2):733–740.
   PubMed Web of Science ®Google Scholar
• Martelli A, Wattenhofer-Donze M, Schmucker S, et al. Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues. Hum Mol Genet. 2007;16(22):2651–2658.
   PubMed Web of Science ®Google Scholar
• Li Y, Lu Y, Polak U, et al. Expanded GAA repeats impede transcription elongation through the FXN gene and induce transcriptional silencing that is restricted to the FXN locus. Hum Mol Genet. 2015;24(24):6932–6943.
   PubMed Web of Science ®Google Scholar
• Groh M, Lufino MM, Wade-Martins R, et al. R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome. PLoS Genet. 2014;10(5):e1004318.
   PubMed Web of Science ®Google Scholar
• Chutake YK, Lam C, Costello WN, et al. Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length. Ann Neurol. 2014;76(4):522–528.
   PubMed Web of Science ®Google Scholar
• Chutake YK, Costello WN, Lam C, et al. Altered nucleosome positioning at the transcription start site and deficient transcriptional initiation in Friedreich ataxia. J Biol Chem. 2014;289(22):15194–15202.
   PubMed Web of Science ®Google Scholar
• Napierala JS, Li Y, Lu Y, et al. Comprehensive analysis of gene expression patterns in Friedreich’s ataxia fibroblasts by RNA sequencing reveals altered levels of protein synthesis factors and solute carriers. Dis Model Mech. 2017;10(11):1353–1369.
   PubMed Web of Science ®Google Scholar
• Pianese L, Turano M, Lo Casale MS, et al. Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J Neurol Neurosurg Psychiatry. 2004;75(7):1061–1063.
   PubMed Web of Science ®Google Scholar
• Sacca F, Puorro G, Antenora A, et al. A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. PLoS One. 2011;6(3):e17627.
   PubMed Web of Science ®Google Scholar
• Wells RD. DNA triplexes and Friedreich ataxia. FASEB J. 2008;22(6):1625–1634.
   PubMed Web of Science ®Google Scholar
• Grabczyk E, Mancuso M, Sammarco MC. A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res. 2007;35(16):5351–5359.
   PubMed Web of Science ®Google Scholar
• Saveliev A, Everett C, Sharpe T, et al. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature. 2003;422(6934):909–913.
   PubMed Web of Science ®Google Scholar
• Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nat Chem Biol. 2006;2(10):551–558.
   PubMed Web of Science ®Google Scholar
• Soragni E, Gottesfeld JM. Translating HDAC inhibitors in Friedreich’s ataxia. Expert Opin Orphan Drugs. 2016;4(9):961–970.
   PubMed Web of Science ®Google Scholar
• Perdomini M, Hick A, Puccio H, et al. Animal and cellular models of Friedreich ataxia. J Neurochem. 2013;126(Suppl 1):65–79.
   PubMedGoogle Scholar
• Puccio H. Multicellular models of Friedreich ataxia. J Neurol. 2009;256(Suppl 1):18–24.
   PubMedGoogle Scholar
• Chandran V, Gao K, Swarup V, et al. Inducible and reversible phenotypes in a novel mouse model of Friedreich’s ataxia. eLife. 2017;6:e30054.
   Web of Science ®Google Scholar
• Anjomani Virmouni S, Ezzatizadeh V, Sandi C, et al. A novel GAA-repeat-expansion-based mouse model of Friedreich’s ataxia. Dis Model Mech. 2015;8(3):225–235.
   PubMed Web of Science ®Google Scholar
• Al-Mahdawi S, Pinto RM, Ruddle P, et al. GAA repeat instability in Friedreich ataxia YAC transgenic mice. Genomics. 2004;84(2):301–310.
   PubMed Web of Science ®Google Scholar
• Miranda CJ, Santos MM, Ohshima K, et al. Frataxin knockin mouse. FEBS Lett. 2002;512(1–3):291–297.
   PubMed Web of Science ®Google Scholar
• Chen K, Ho TS, Lin G, et al. Loss of Frataxin activates the iron/sphingolipid/PDK1/Mef2 pathway in mammals. eLife. 2016;5:e20732.
   Web of Science ®Google Scholar
• Cossee M, Puccio H, Gansmuller A, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet. 2000;9(8):1219–1226.
   PubMed Web of Science ®Google Scholar
• Klimanskaya I, Chung Y, Becker S, et al. Human embryonic stem cell lines derived from single blastomeres. Nature. 2006;444(7118):481–485.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872.
   PubMed Web of Science ®Google Scholar
• Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–1920.
   PubMed Web of Science ®Google Scholar
• Malik N, Rao M. S. A review of the methods for human iPSC derivation. Methods Mol Biol. 2013;997:23–33.
   PubMedGoogle Scholar
• Jaworska E, Kozlowska E, Switonski PM, et al. Modeling simple repeat expansion diseases with iPSC technology. Cell Mol Life Sci. 2016;73(21):4085–4100.
   PubMed Web of Science ®Google Scholar
• Garreta E, Sanchez S, Lajara J, et al. Roadblocks in the Path of iPSC to the clinic. Curr Transplant Rep. 2018;5(1):14–18.
   PubMedGoogle Scholar
• Ku S, Soragni E, Campau E, et al. Friedreich’s ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability. Cell Stem Cell. 2010;7(5):631–637.
   PubMed Web of Science ®Google Scholar
• Du J, Campau E, Soragni E, et al. Role of mismatch repair enzymes in GAA.TTC triplet-repeat expansion in Friedreich ataxia induced pluripotent stem cells. J Biol Chem. 2012;287(35):29861–29872.
   PubMed Web of Science ®Google Scholar
• Ditch S, Sammarco MC, Banerjee A, et al. Progressive GAA.TTC repeat expansion in human cell lines. PLoS Genet. 2009;5(10):e1000704.
   PubMed Web of Science ®Google Scholar
• Dion V, Wilson JH. Instability and chromatin structure of expanded trinucleotide repeats. Trends Genet. 2009;25(7):288–297.
   PubMed Web of Science ®Google Scholar
• Halabi A, Ditch S, Wang J, et al. DNA mismatch repair complex MutSbeta promotes GAA.TTC repeat expansion in human cells. J Biol Chem. 2012;287(35):29958–29967.
   PubMed Web of Science ®Google Scholar
• Halabi A, Fuselier KTB, Grabczyk E. GAA*TTC repeat expansion in human cells is mediated by mismatch repair complex MutLgamma and depends upon the endonuclease domain in MLH3 isoform one. Nucleic Acids Res. 2018;46(8):4022–4032.
   PubMed Web of Science ®Google Scholar
• Gerhardt J, Bhalla AD, Butler JS, et al. Stalled DNA replication forks at the endogenous GAA repeats drive repeat expansion in Friedreich’s ataxia cells. Cell Rep. 2016;16(5):1218–1227.
   PubMed Web of Science ®Google Scholar
• Polak U, Li Y, Butler JS, et al. Alleviating GAA repeat induced transcriptional silencing of the Friedreich’s ataxia gene during somatic cell reprogramming. Stem Cells Dev. 2016;25(23):1788–1800.
   PubMed Web of Science ®Google Scholar
• Liu J, Verma PJ, Evans-Galea MV, et al. Generation of induced pluripotent stem cell lines from Friedreich ataxia patients. Stem Cell Rev. 2011;7(3):703–713.
   PubMed Web of Science ®Google Scholar
• Hu A, Rai M, Donatello S, et al. Oxidative stress and loss of Fe-S proteins in Friedreich ataxia induced pluripotent stem cell-derived PSNs can be reversed by restoring FXN expression with a benzamide HDAC inhibitor. bioRxiv. 2017. DOI:10.1101/221242.
   Google Scholar
• Shan B, Xu C, Zhang Y, et al. Quantitative proteomic analysis identifies targets and pathways of a 2-aminobenzamide HDAC inhibitor in Friedreich’s ataxia patient iPSC-derived neural stem cells. J Proteome Res. 2014;13(11):4558–4566.
   PubMed Web of Science ®Google Scholar
• Soragni E, Miao W, Iudicello M, et al. Epigenetic therapy for Friedreich ataxia. Ann Neurol. 2014;76(4):489–508.
   PubMed Web of Science ®Google Scholar
• Bird MJ, Needham K, Frazier AE, et al. Functional characterization of Friedreich ataxia iPS-derived neuronal progenitors and their integration in the adult brain. PLoS One. 2014;9(7):e101718.
   PubMed Web of Science ®Google Scholar
• Marmolino D. Friedreich’s ataxia: past, present and future. Brain Res Rev. 2011;67(1–2):311–330.
   PubMedGoogle Scholar
• Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol. 2009;256(Suppl 1):3–8.
   PubMedGoogle Scholar
• Lynch DR, Deutsch EC, Wilson RB, et al. Unanswered questions in Friedreich ataxia. J Child Neurol. 2012;27(9):1223–1229.
   PubMed Web of Science ®Google Scholar
• Hick A, Wattenhofer-Donze M, Chintawar S, et al. Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich’s ataxia. Dis Model Mech. 2013;6(3):608–621.
   PubMed Web of Science ®Google Scholar
• Eigentler A, Boesch S, Schneider R, et al. Induced pluripotent stem cells from friedreich ataxia patients fail to upregulate frataxin during in vitro differentiation to peripheral sensory neurons. Stem Cells Dev. 2013;22(24):3271–3282.
   PubMed Web of Science ®Google Scholar
• Soragni E, Chou CJ, Rusche JR, et al. Mechanism of action of 2-Aminobenzamide HDAC inhibitors in reversing gene silencing in Friedreich’s ataxia. Front Neurol. 2015;6:44.
   PubMed Web of Science ®Google Scholar
• Codazzi F, Hu A, Rai M, et al. Friedreich ataxia-induced pluripotent stem cell-derived neurons show a cellular phenotype that is corrected by a benzamide HDAC inhibitor. Hum Mol Genet. 2016;25(22):4847–4855.
   PubMed Web of Science ®Google Scholar
• Erwin GS, Grieshop MP, Ali A, et al. Synthetic transcription elongation factors license transcription across repressive chromatin. Science. 2017;358(6370):1617–1622.
   PubMed Web of Science ®Google Scholar
• Li Y, Polak U, Bhalla AD, et al. Excision of expanded GAA repeats alleviates the molecular phenotype of Friedreich’s ataxia. Mol Ther. 2015;23(6):1055–1065.
   PubMed Web of Science ®Google Scholar
• Igoillo-Esteve M, Gurgul-Convey E, Hu A, et al. Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich’s ataxia. Hum Mol Genet. 2015;24(8):2274–2286.
   PubMed Web of Science ®Google Scholar
• Payne RM, Wagner GR. Cardiomyopathy in Friedreich ataxia: clinical findings and research. J Child Neurol. 2012;27(9):1179–1186.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Regner SR, Schadt KA, et al. Management and therapy for cardiomyopathy in Friedreich’s ataxia. Expert Rev Cardiovasc Ther. 2012;10(6):767–777.
   PubMedGoogle Scholar
• Perdomini M, Belbellaa B, Monassier L, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich’s ataxia. Nat Med. 2014;20(5):542–547.
   PubMed Web of Science ®Google Scholar
• Ramirez RL, Becker AB, Mazurkiewicz JE, et al. Pathology of intercalated discs in Friedreich cardiomyopathy. J Am Coll Cardiol. 2015;66(15):1739–1740.
   PubMed Web of Science ®Google Scholar
• Lee YK, Ho PW, Schick R, et al. Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells. Pflugers Arch. 2014;466(9):1831–1844.
   PubMed Web of Science ®Google Scholar
• Lee YK, Lau YM, Ng KM, et al. Efficient attenuation of Friedreich’s ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA. Int J Cardiol. 2016;203:964–971.
   PubMed Web of Science ®Google Scholar
• Crombie DE, Curl CL, Raaijmakers AJ, et al. Friedreich’s ataxia induced pluripotent stem cell-derived cardiomyocytes display electrophysiological abnormalities and calcium handling deficiency. Aging (Albany NY). 2017;9(5):1440–1452.
   PubMedGoogle Scholar
• Martins AM, Vunjak-Novakovic G, Reis RL. The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine. Stem Cell Rev. 2014;10(2):177–190.
   PubMed Web of Science ®Google Scholar
• Pandolfo M. Friedreich ataxia. Semin Pediatr Neurol. 2003;10(3):163–172.
   PubMedGoogle Scholar
• Fortuna F, Barboni P, Liguori R, et al. Visual system involvement in patients with Friedreich’s ataxia. Brain. 2009;132(Pt 1):116–123.
   PubMed Web of Science ®Google Scholar
• Rance G, Corben L, Barker E, et al. Auditory perception in individuals with Friedreich’s ataxia. Audiol Neurootol. 2010;15(4):229–240.
   PubMed Web of Science ®Google Scholar
• Crombie DE, Van Bergen N, Davidson KC, et al. Characterization of the retinal pigment epithelium in Friedreich ataxia. Biochem Biophys Rep. 2015;4:141–147.
   PubMedGoogle Scholar
• Lupoli F, Vannocci T, Longo G, et al. The role of oxidative stress in Friedreich’s ataxia. FEBS Lett. 2018;592(5):718–727.
   PubMed Web of Science ®Google Scholar
• Vannocci T, Notario Manzano R, Beccalli O, et al. Adding a temporal dimension to the study of Friedreich’s ataxia: the effect of frataxin overexpression in a human cell model. Dis Model Mech. 2018;11: 6.
   Web of Science ®Google Scholar
• Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7):397–405.
   PubMed Web of Science ®Google Scholar
• Knott GJJA. Doudna, CRISPR-Cas guides the future of genetic engineering. Science. 2018;361(6405):866–869.
   PubMed Web of Science ®Google Scholar
• Xu X, Tay Y, Sim B, et al. Reversal of phenotypic abnormalities by CRISPR/Cas9-mediated gene correction in huntington disease patient-derived induced pluripotent stem cells. Stem Cell Reports. 2017;8(3):619–633.
   PubMed Web of Science ®Google Scholar
• An MC, O’Brien RN, Zhang N, et al. Polyglutamine disease modeling: epitope based screen for homologous recombination using CRISPR/Cas9 System. PLoS Curr. 2014;6. doi: 10.1371/currents.hd.0242d2e7ad72225efa72f6964589369a.
   Google Scholar
• Cinesi C, Aeschbach L, Yang B, et al. Contracting CAG/CTG repeats using the CRISPR-Cas9 nickase. Nat Commun. 2016;7:13272.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim S. A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014;15(5):321–334.
   PubMed Web of Science ®Google Scholar
• Liang G, Zhang Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell. 2013;13(2):149–159.
   PubMed Web of Science ®Google Scholar
• Miller JD, Ganat YM, Kishinevsky S, et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell. 2013;13(6):691–705.
   PubMed Web of Science ®Google Scholar
• Mertens J, Paquola ACM, Ku M, et al. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell. 2015;17(6):705–718.
   PubMed Web of Science ®Google Scholar
• Mertens J, Reid D, Lau S, et al. Aging in a dish: iPSC-Derived and directly induced neurons for studying brain aging and age-related neurodegenerative diseases. Annu Rev Genet. 2018;52:271–293.
   PubMed Web of Science ®Google Scholar
• Tsunemoto R, Lee S, Szucs A, et al. Diverse reprogramming codes for neuronal identity. Nature. 2018;557(7705):375–380.
   PubMed Web of Science ®Google Scholar
• Pasca SP. The rise of three-dimensional human brain cultures. Nature. 2018;553(7689):437–445.
   PubMed Web of Science ®Google Scholar
• Vinci M, Gowan S, Boxall F, et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012;10:29.
   PubMed Web of Science ®Google Scholar
• Ravi M, Paramesh V, Kaviya SR, et al. 3D cell culture systems: advantages and applications. J Cell Physiol. 2015;230(1):16–26.
   PubMed Web of Science ®Google Scholar
• Dutta D, Heo I, Clevers H. Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med. 2017;23(5):393–410.
   PubMed Web of Science ®Google Scholar
• Ware CB. Concise review: lessons from Naive human pluripotent cells. Stem Cells. 2017;35(1):35–41.
   PubMed Web of Science ®Google Scholar
• Huang K, Maruyama T, Fan G. The naive state of human pluripotent stem cells: a synthesis of stem cell and preimplantation embryo transcriptome analyses. Cell Stem Cell. 2014;15(4):410–415.
   PubMed Web of Science ®Google Scholar
• Manor YS, Massarwa R, Hanna JH. Establishing the human naive pluripotent state. Curr Opin Genet Dev. 2015;34:35–45.
   PubMed Web of Science ®Google Scholar
• Gafni O, Weinberger L, Mansour AA, et al. Derivation of novel human ground state naive pluripotent stem cells. Nature. 2013;504(7479):282–286.
   PubMed Web of Science ®Google Scholar